Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 380 clinical trials
featured
Albuterol in Patients With Lymphangioleiomyomatosis

to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol

lymphangioleiomyomatosis
  • 16 views
  • 22 Dec, 2020
  • 1 location
featured
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it. Objectives: To discover new pathways that are involved in pulmonary fibrosis. To develop new …

idiopathic pulmonary fibrosis
chest x-ray
walk tests
chest ct
ct scan
  • 162 views
  • 23 Nov, 2020
  • 1 location
featured
A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

  • 136 views
  • 08 Nov, 2020
  • 1 location
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)

docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1

  • 3 views
  • 17 Sep, 2021
  • 53 locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib

biomarker analysis
measurable disease
progressive disease
docetaxel
ct scan
  • 151 views
  • 09 Sep, 2021
  • 151 locations
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more …

dactinomycin
conventional surgery
ifosfamide
tumor cells
etoposide
  • 103 views
  • 07 Nov, 2020
  • 9 locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

measurable disease
docetaxel
systemic therapy
epidermal growth factor receptor
lung carcinoma
  • 0 views
  • 18 Jul, 2021
  • 44 locations
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant …

  • 171 views
  • 22 Aug, 2021
  • 129 locations
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant and the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the OncotypeDX …

white blood cells
neutrophil count
goserelin 3.6 mg
cancer treatment
fulvestrant
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 26 Aug, 2021
  • 83 locations